Complete response to therapy: why do primary central nervous system lymphoma patients not return to work?
Neurocognition
Primary central nervous system lymphoma
Quality of life
Return to work
Social integration
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
21
04
2020
accepted:
23
07
2020
pubmed:
2
8
2020
medline:
22
6
2021
entrez:
2
8
2020
Statut:
ppublish
Résumé
Although primary central nervous system lymphomas (PCNSL) represent extremely aggressive brain tumours, high-dose methotrexate in combination with other chemotherapeutic agents has resulted in long-term disease control in a substantial fraction of patients. Advances in treatment efficacy with longer survival resulted in a focus on additional outcome measures such as quality of life (QoL) and neurocognition. Despite recent evidence of return to work as an important aspect of patients' QoL, little is known about occupational reintegration in PCNSL long-term survivors. This study aimed to detect specific characteristics of patients who successfully resumed work after complete response to therapy. Patients with ongoing complete response to therapy completed a test battery capturing neurocognition, social integration, QoL and psychological burden. Of 25 patients who had been in regular employment before diagnosis only eight returned to work after treatment (32%). Patients who resumed work rated important aspects of their QoL and social integration as higher and suffered less from symptoms affecting QoL than patients who did not resume work. Also, the subjective confidence in their ability to work was higher in patients who resumed work, but independent predictors of return to work were not found in logistic regression analyses. Occupational (re)integration is of clinical relevance in PCNSL patients after complete response to therapy. Due to the small size of our cohort the present results should be considered an exploratory first step. Return to work might be a crucial aspect of QoL and (re)integration into society after cure of PCNSL.
Identifiants
pubmed: 32737735
doi: 10.1007/s11060-020-03587-5
pii: 10.1007/s11060-020-03587-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-179Références
Batchelor TT (2019) Primary central nervous system lymphoma: a curable disease. Hematol Oncol 37(Suppl 1):15–18. https://doi.org/10.1002/hon.2598
doi: 10.1002/hon.2598
pubmed: 31187523
Villano JL, Koshy M, Shaikh H et al (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105(9):1414–1418. https://doi.org/10.1038/bjc.2011.357
doi: 10.1038/bjc.2011.357
pubmed: 21915121
pmcid: 3241537
Seidel S, Schlegel U (2019) Have treatment protocols for primary CNS lymphoma advanced in the past 10 years. Expert Rev Anticancer Ther 19(10):909–915. https://doi.org/10.1080/14737140.2019.1677157
doi: 10.1080/14737140.2019.1677157
pubmed: 31594423
Harder H, Holtel H, Bromberg JEC et al (2004) Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62(4):544–547. https://doi.org/10.1212/wnl.62.4.544
doi: 10.1212/wnl.62.4.544
pubmed: 14981168
Correa DD, Maron L, Harder H et al (2007) Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 18(7):1145–1151. https://doi.org/10.1093/annonc/mdl464
doi: 10.1093/annonc/mdl464
pubmed: 17284616
Correa DD, Shi W, Abrey LE et al (2012) Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro-oncology 14(1):101–108. https://doi.org/10.1093/neuonc/nor186
doi: 10.1093/neuonc/nor186
pubmed: 22013168
Thiel E, Korfel A, Martus P et al (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11(11):1036–1047. https://doi.org/10.1016/S1470-2045(10)70229-1
doi: 10.1016/S1470-2045(10)70229-1
pubmed: 20970380
Seidel S, Korfel A, Kowalski T et al (2019) HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis. Neurol Res Pract 1(1):iv1. https://doi.org/10.1186/s42466-019-0024-2
doi: 10.1186/s42466-019-0024-2
Hoffman MA, Lent RW, Raque-Bogdan TL (2013) A social cognitive perspective on coping with cancer. Couns Psychol 41(2):240–267. https://doi.org/10.1177/0011000012461378
doi: 10.1177/0011000012461378
Fliessbach K, Helmstaedter C, Urbach H et al (2005) Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 64(7):1184–1188. https://doi.org/10.1212/01.WNL.0000156350.49336.E2
doi: 10.1212/01.WNL.0000156350.49336.E2
pubmed: 15824344
Juergens A, Pels H, Rogowski S et al (2010) Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 67(2):182–189. https://doi.org/10.1002/ana.21824
doi: 10.1002/ana.21824
pubmed: 20225195
Doolittle ND, Korfel A, Lubow MA et al (2013) Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology 81(1):84–92. https://doi.org/10.1212/WNL.0b013e318297eeba
doi: 10.1212/WNL.0b013e318297eeba
pubmed: 23685932
pmcid: 3770201
Vargo M, Henriksson R, Salander P (2016) Rehabilitation of patients with glioma. Handb Clin Neurol 134:287–304. https://doi.org/10.1016/B978-0-12-802997-8.00017-7
doi: 10.1016/B978-0-12-802997-8.00017-7
pubmed: 26948361
Kaplan CP, Miner ME (1997) Anxiety and depression in elderly patients receiving treatment for cerebral tumours. Brain Inj 11(2):129–135
doi: 10.1080/026990597123728
Ozbay F, Johnson DC, Dimoulas E et al (2007) Social support and resilience to stress: from neurobiology to clinical practice. Psychiatry 4(5):35–40
pubmed: 20806028
Gheaus A, Herzog L (2016) The goods of work (other than money!). J Soc Philos 47(1):70–89. https://doi.org/10.1111/josp.12140
doi: 10.1111/josp.12140
Hanson A (2007) Workplace health promotion: a salutogenic approach. AuthorHouse, Bloomington
Saunders SL, Nedelec B (2014) What work means to people with work disability: a scoping review. J Occup Rehabil 24(1):100–110. https://doi.org/10.1007/s10926-013-9436-y
doi: 10.1007/s10926-013-9436-y
pubmed: 23519737
Alaszewski A, Alaszewski H, Potter J et al (2007) Working after a stroke: survivors' experiences and perceptions of barriers to and facilitators of the return to paid employment. Disabil Rehabil 29(24):1858–1869. https://doi.org/10.1080/09638280601143356
doi: 10.1080/09638280601143356
pubmed: 17852252
Main DS, Nowels CT, Cavender TA et al (2005) A qualitative study of work and work return in cancer survivors. Psycho-Oncology 14(11):992–1004. https://doi.org/10.1002/pon.913
doi: 10.1002/pon.913
pubmed: 15744780
Karnofsky DA, Abelmann WH, Craver LF et al (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer 1(4):634–656
doi: 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L
Péus D, Newcomb N, Hofer S (2013) Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation. BMC Med Inform Decis Mak 13:72. https://doi.org/10.1186/1472-6947-13-72
doi: 10.1186/1472-6947-13-72
pubmed: 23870327
pmcid: 3722041
Ebener M (ed) (2013) Why WAI?: Der Work Ability Index im Einsatz für Arbeitsfähigkeit und Prävention - Erfahrungsberichte aus der Praxis, 5. Aufl., Dezember 2013. Bundesanst. für Arbeitsschutz und Arbeitsmedizin (BAuA), Dortmund
Callaway L, Winkler D, Tippett A et al (2016) The community integration questionnaire—revised: Australian normative data and measurement of electronic social networking. Aust Occup Ther J 63(3):143–153. https://doi.org/10.1111/1440-1630.12284
doi: 10.1111/1440-1630.12284
pubmed: 27072343
Willer B, Ottenbacher KJ, Coad ML (1994) The community integration questionnaire. A comparative examination. Am J Phys Med Rehabil 73(2):103–111. https://doi.org/10.1097/00002060-199404000-00006
doi: 10.1097/00002060-199404000-00006
pubmed: 8148099
Fliessbach K, Rogowski S, Hoppe C et al (2010) Computer-based assessment of cognitive functions in brain tumor patients. J Neurooncol 100(3):427–437. https://doi.org/10.1007/s11060-010-0194-9
doi: 10.1007/s11060-010-0194-9
pubmed: 20449630
Fliessbach K, Hoppe C, Schlegel U et al (2006) NeuroCogFX–eine computergestützte neuropsychologische Testbatterie für Verlaufsuntersuchungen bei neurologischen Erkrankungen (NeuroCogFX–a computer-based neuropsychological assessment battery for the follow-up examination of neurological patients). Fortschr Neurol Psychiatr 74(11):643–650. https://doi.org/10.1055/s-2006-932162
doi: 10.1055/s-2006-932162
pubmed: 17103364
Flechl B, Ackerl M, Sax C et al (2012) Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors. J Neurooncol 109(2):331–339. https://doi.org/10.1007/s11060-012-0897-1
doi: 10.1007/s11060-012-0897-1
pubmed: 22644537
Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376. https://doi.org/10.1093/jnci/85.5.365
doi: 10.1093/jnci/85.5.365
pubmed: 8433390
Taphoorn MJB, Claassens L, Aaronson NK et al (2010) An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer 46(6):1033–1040. https://doi.org/10.1016/j.ejca.2010.01.012
doi: 10.1016/j.ejca.2010.01.012
pubmed: 20181476
Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x
doi: 10.1111/j.1600-0447.1983.tb09716.x
pubmed: 6880820
Cocchiara RA, Sciarra I, D’Egidio V et al (2018) Returning to work after breast cancer: a systematic review of reviews. Work 61(3):463–476. https://doi.org/10.3233/WOR-182810
doi: 10.3233/WOR-182810
pubmed: 30400123
de Boer AGEM, Taskila T, Ojajärvi A et al (2009) Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA 301(7):753–762. https://doi.org/10.1001/jama.2009.187
doi: 10.1001/jama.2009.187
pubmed: 19224752
Starnoni D, Berthiller J, Idriceanu T-M et al (2018) Returning to work after multimodal treatment in glioblastoma patients. Neurosurg Focus 44(6):E17. https://doi.org/10.3171/2018.3.FOCUS1819
doi: 10.3171/2018.3.FOCUS1819
pubmed: 29852767
Gzell C, Wheeler H, Guo L et al (2014) Employment following chemoradiotherapy in glioblastoma: a prospective case series. J Cancer Surviv 8(1):108–113. https://doi.org/10.1007/s11764-013-0311-9
doi: 10.1007/s11764-013-0311-9
pubmed: 24214496
Hodson DJ, Bowles KM, Cooke LJ et al (2005) Primary central nervous system lymphoma: a single-centre experience of 55 unselected cases. Clin Oncol 17(3):185–191. https://doi.org/10.1016/j.clon.2004.10.007
doi: 10.1016/j.clon.2004.10.007
Kiewe P, Fischer L, Martus P et al (2008) Primary central nervous system lymphoma. Cancer 112(8):1812–1820. https://doi.org/10.1002/cncr.23377
doi: 10.1002/cncr.23377
pubmed: 18318432
Hoofien D, Gilboa A, Vakil E et al (2001) Traumatic brain injury (TBI) 10–20 years later: a comprehensive outcome study of psychiatric symptomatology, cognitive abilities and psychosocial functioning. Brain Inj 15(3):189–209. https://doi.org/10.1080/026990501300005659
doi: 10.1080/026990501300005659
pubmed: 11260769
Nazarov S, Manuwald U, Leonardi M et al (2019) Chronic diseases and employment: which interventions support the maintenance of work and return to work among workers with chronic illnesses? A systematic review. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph16101864
doi: 10.3390/ijerph16101864
pubmed: 31137817
pmcid: 6572561